Neumora Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-ARCH Venture Fund VII, L.P.(20.9%),ARCH Venture Fund VIII Overage, L.P.(20.9%), etc.

SEC announcement · Dec 16, 2023 06:06

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Neumora Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-ARCH Venture Fund VII, L.P.(20.9%),ARCH Venture Fund VIII Overage, L.P.(20.9%), etc.

Risk Disclaimer